论文部分内容阅读
目的检测多囊卵巢综合征(PCOS)胰岛素抵抗患者卵巢颗粒细胞中microRNA-183(miR-183)的表达,并评价其临床意义。方法采用实时荧光定量逆转录聚合酶链反应(qRT-PCR)检测120例PCOS患者[其中78例PCOS胰岛素抵抗患者(PCOS胰岛素抵抗组)和42例PCOS非胰岛素抵抗患者(PCOS非胰岛素抵抗组)及72例正常对照者(正常对照组)]颗粒细胞中miR-183的表达,并对miR-183表达和胰岛素抵抗指数(HOMA-IR)进行关联分析,同时对组间临床资料进行回顾性分析。采用受试者工作特征(ROC)曲线评价miR-183的诊断效能。结果 miR-183在PCOS胰岛素抵抗组颗粒细胞中的表达高于正常对照组(P<0.001)及非胰岛素抵抗组(P=0.034),PCOS胰岛素抵抗组miR-183的表达与HOM A-IR呈正相关(r=0.476,P=0.003),ROC曲线提示miR-183联合体质量指数(BM I)作为PCOS胰岛素抵抗的评价指标,其诊断效能较高(AUC:0.820,95%CI:0.750~0.889,P<0.001)。结论 miR-183在PCOS胰岛素抵抗患者颗粒细胞中高表达,并与HOM A-IR相关,其可能通过卵泡局部微环境参与调控PCOS胰岛素抵抗的致病过程。
Objective To detect the expression of microRNA-183 (miR-183) in ovarian granulosa cells of patients with insulin resistance of polycystic ovary syndrome (PCOS) and evaluate its clinical significance. Methods A total of 120 PCOS patients (78 PCOS insulin resistance patients and 42 PCOS non-insulin resistance patients (PCOS non-insulin resistance group) were detected by real-time quantitative reverse transcription-polymerase chain reaction (qRT- And 72 normal controls (normal control group)] granulosa cells, miR-183 expression and insulin resistance index (HOMA-IR) were analyzed, and the clinical data were retrospectively analyzed . Subject performance characteristics (ROC) curves were used to assess the diagnostic efficacy of miR-183. Results The expression of miR-183 in PCOS group was higher than that in normal control group (P <0.001) and non-insulin resistance group (P = 0.034). The expression of miR-183 in PCOS insulin resistance group was positively correlated with HOM A-IR (R = 0.476, P = 0.003). The ROC curve suggested that the diagnostic value of miR-183 combined body mass index (BMI) as a marker of PCOS insulin resistance was higher (AUC: 0.820, 95% CI: 0.750-0.889 , P <0.001). Conclusion miR-183 is highly expressed in granulosa cells of PCOS patients with insulin resistance and is associated with HOM A-IR. It may be involved in the pathogenesis of insulin resistance in PCOS through the local microenvironment of follicles.